JP5951480B2 - オンデマンド避妊方法 - Google Patents
オンデマンド避妊方法 Download PDFInfo
- Publication number
- JP5951480B2 JP5951480B2 JP2012505146A JP2012505146A JP5951480B2 JP 5951480 B2 JP5951480 B2 JP 5951480B2 JP 2012505146 A JP2012505146 A JP 2012505146A JP 2012505146 A JP2012505146 A JP 2012505146A JP 5951480 B2 JP5951480 B2 JP 5951480B2
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- ulipristal acetate
- progesterone receptor
- use according
- demand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003433 contraceptive agent Substances 0.000 title description 22
- 238000000034 method Methods 0.000 title description 22
- 230000002254 contraceptive effect Effects 0.000 title description 15
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims description 39
- 229960000499 ulipristal acetate Drugs 0.000 claims description 30
- 230000001568 sexual effect Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 11
- 230000027758 ovulation cycle Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 6
- HKDLNTKNLJPAIY-WKWWZUSTSA-N Ulipristal Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-WKWWZUSTSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000000583 progesterone congener Substances 0.000 description 34
- 239000002379 progesterone receptor modulator Substances 0.000 description 32
- 239000003795 chemical substances by application Substances 0.000 description 26
- 239000002207 metabolite Substances 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 11
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 10
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 5
- 229940124558 contraceptive agent Drugs 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- -1 17-hydroxyprogesterone ester Chemical class 0.000 description 4
- 239000007891 compressed tablet Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000000938 luteal effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HKDLNTKNLJPAIY-DWWOYTEKSA-N (8s,13s,14s,17r)-17-acetyl-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1C1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-DWWOYTEKSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 description 1
- ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960002692 allylestrenol Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
- 229940095053 emergency contraceptive drug Drugs 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 229960002831 norgestrienone Drugs 0.000 description 1
- GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003408 postcoitus contraceptive agent Substances 0.000 description 1
- 230000000136 postovulatory effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Separation By Low-Temperature Treatments (AREA)
Description
本発明は、プロゲストゲン剤またはプロゲステロンレセプターモジュレーターを女性に***前72時間以内にオンデマンドで投与することを含む、該投与を1週間に少なくとも1回反復することができる避妊方法を提供する。
本発明者らは、酢酸ウリプリスタルを緊急避妊薬としてのみならず、定期的ホルモン避妊薬としても用いることができるか否かについて試験した。
プロゲストゲン剤:
プロゲステロンレセプターモジュレーター:
オンデマンド(要求に応じた):
プロゲストゲン剤またはプロゲステロンレセプターモジュレーター、例えば酢酸ウリプリスタルまたはその代謝物は、経口、バッカル、舌下、非経口的、経皮、膣内、直腸内などを含むあらゆる好都合な経路で投与することができる。
用量
投与計画:
複数の女性が、月経周期中に2回、公表した***後に酢酸ウリプリスタル (30 mg)を摂取した。
Claims (8)
- 女性に避妊をもたらすための医薬を製造するための、17α-アセトキシ-11β-[4-N,N-ジメチルアミノ-フェニル)-19-ノルプレグナ-4,9-ジエン-3,20-ジオン (酢酸ウリプリスタル)の使用であって、該医薬が酢酸ウリプリスタルを10〜40mgの用量で含み、該医薬を女性に***後72〜120時間以内に経口投与する使用。
- 該医薬の投与を、女性に1月間に少なくとも2回反復する請求項1記載の使用。
- 該医薬が酢酸ウリプリスタルを30mgの用量で含む請求項1または2に記載の使用。
- 該医薬が酢酸ウリプリスタルを20mgの用量で含む請求項1または2に記載の使用。
- 該医薬の投与を1週間に1回反復する請求項1〜4のいずれかに記載の使用。
- 該医薬の投与を月経周期中に3回反復する請求項1〜4のいずれかに記載の使用。
- 該医薬を連続4日間以下で投与する請求項1〜4のいずれかに記載の使用。
- 該医薬を連続2日間以下で投与する請求項1〜4のいずれかに記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16914909P | 2009-04-14 | 2009-04-14 | |
US61/169,149 | 2009-04-14 | ||
PCT/EP2010/054812 WO2010119029A1 (en) | 2009-04-14 | 2010-04-13 | Method for on-demand contraception |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016114491A Division JP2016188232A (ja) | 2009-04-14 | 2016-06-08 | オンデマンド避妊方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012523446A JP2012523446A (ja) | 2012-10-04 |
JP5951480B2 true JP5951480B2 (ja) | 2016-07-13 |
Family
ID=42309669
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012505146A Active JP5951480B2 (ja) | 2009-04-14 | 2010-04-13 | オンデマンド避妊方法 |
JP2016114491A Pending JP2016188232A (ja) | 2009-04-14 | 2016-06-08 | オンデマンド避妊方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016114491A Pending JP2016188232A (ja) | 2009-04-14 | 2016-06-08 | オンデマンド避妊方法 |
Country Status (25)
Country | Link |
---|---|
US (4) | US9616073B2 (ja) |
EP (2) | EP2419108B1 (ja) |
JP (2) | JP5951480B2 (ja) |
CN (1) | CN102395373A (ja) |
AU (1) | AU2010237120B8 (ja) |
BR (1) | BRPI1014035A2 (ja) |
CA (1) | CA2757496A1 (ja) |
CY (1) | CY1118236T1 (ja) |
DK (1) | DK2419108T3 (ja) |
ES (1) | ES2602134T3 (ja) |
HK (1) | HK1232150A1 (ja) |
HR (1) | HRP20161437T1 (ja) |
HU (1) | HUE029434T2 (ja) |
IL (1) | IL215524A0 (ja) |
LT (1) | LT2419108T (ja) |
ME (1) | ME02548B (ja) |
NZ (2) | NZ615430A (ja) |
PL (1) | PL2419108T3 (ja) |
PT (1) | PT2419108T (ja) |
RS (1) | RS55331B1 (ja) |
RU (1) | RU2542779C2 (ja) |
SI (1) | SI2419108T1 (ja) |
SM (1) | SMT201600399B (ja) |
WO (1) | WO2010119029A1 (ja) |
ZA (1) | ZA201107543B (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
EP2419108B1 (en) | 2009-04-14 | 2016-08-17 | Laboratoire HRA Pharma | Method for on-demand contraception |
DE202011110355U1 (de) * | 2011-03-09 | 2014-01-15 | Arstat, Inc. | Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes |
CN102727457B (zh) * | 2011-04-08 | 2014-05-28 | 华润紫竹药业有限公司 | 稳定的醋酸优力司特制剂 |
FR2987271B1 (fr) | 2012-02-28 | 2017-08-18 | Hra Pharma Lab | Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens |
JP2015532263A (ja) | 2012-09-28 | 2015-11-09 | あすか製薬株式会社 | ウリプリスタール酢酸エステルの結晶多形 |
JP6200493B2 (ja) | 2012-09-28 | 2017-09-20 | あすか製薬株式会社 | 無定形ウリプリスタール酢酸エステル |
AU2013321890B2 (en) | 2012-09-28 | 2017-05-18 | Aska Pharmaceutical Co., Ltd. | Crystalline polymorphic form of ulipristal acetate |
FR2997628B1 (fr) | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone |
FR2997627B1 (fr) | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant de l'ulipristal acetate |
CN104797258A (zh) | 2012-11-22 | 2015-07-22 | 拜耳药业股份公司 | 包含左炔诺孕酮和cox抑制剂的药物组合物用于按需避孕的用途和施用方法 |
FR2999081B1 (fr) | 2012-12-06 | 2015-02-27 | Hra Pharma Lab | Dispersion solide d'un modulateur selectif du recepteur a la progesterone |
CN103006595B (zh) * | 2012-12-25 | 2018-04-06 | 江苏亚邦爱普森药业有限公司 | 制备醋酸优力司特片的方法 |
JP6370887B2 (ja) | 2013-05-23 | 2018-08-08 | バイエル・ファルマ・アクティエンゲゼルシャフト | オンデマンド避妊のための医薬組成物およびその使用、ならびにこの医薬組成物の適用体制 |
FR3060389B1 (fr) | 2016-12-20 | 2019-05-31 | Laboratoire Hra-Pharma | Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites |
WO2017216637A2 (en) | 2017-08-04 | 2017-12-21 | Alvogen Malta Operations (Row) Ltd | Tablet form including ulipristal acetate and the methods for its preparation |
WO2019204163A1 (en) | 2018-04-20 | 2019-10-24 | Tessenderlo Kerley, Inc. | Liquid nitrogen fertilizer compositions and additives therefore |
EP3575278A1 (en) | 2018-05-31 | 2019-12-04 | Tessenderlo Kerley, Inc. | Liquid nitrogen fertilizer compositions and additives therefor |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6A (en) * | 1836-08-10 | Thomas blanghard | ||
DE1922005A1 (de) | 1969-04-24 | 1970-11-05 | Schering Ag | Mittel und Methode zur Kontrazeption |
US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
DE4405898A1 (de) | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
ES2279515T3 (es) | 1994-10-24 | 2007-08-16 | Bayer Schering Pharma Aktiengesellschaft | Antagonistas competitivos de la progesterona para el control de la fertilidad femenina, orientado a las necesidades de uso. |
US5929262A (en) | 1995-03-30 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates |
EP1098653A2 (en) * | 1998-07-17 | 2001-05-16 | PHARMACIA & UPJOHN COMPANY | Subcutaneous medroxyprogesterone acetate for contraception |
AU5619399A (en) * | 1998-08-11 | 2000-03-06 | Akzo Nobel N.V. | Progestogen-only contraceptive kit providing good cycle control |
IL148415A0 (en) | 1999-08-31 | 2002-09-12 | Jenapharm Gmbh | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives |
ES2546291T3 (es) * | 2000-03-17 | 2015-09-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | 17-Alfa-sustituida, 11-beta-sustituida-4-arilo y 21-sustituida 19-norpregnadienodionas como agentes antiprogestacionales |
HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
ES2212912B1 (es) * | 2003-01-22 | 2005-10-01 | Crystal Pharma, S.A. | Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona. |
AU2004217988C1 (en) | 2003-02-28 | 2010-06-03 | Southwest Foundation For Biomedical Research | Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates |
GT200500186A (es) | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
CN1980660A (zh) * | 2004-07-07 | 2007-06-13 | 惠氏公司 | 孕酮受体拮抗剂的避孕方案和试剂盒 |
CA2573266C (en) | 2004-07-09 | 2011-11-08 | The Population Council, Inc. | Sustained release compositions containing progesterone receptor modulators |
CA2623678A1 (en) | 2005-09-29 | 2007-04-05 | Repros Therapeutics Inc. | Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride |
DE102005050729A1 (de) | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
US7867515B2 (en) * | 2006-12-20 | 2011-01-11 | TEVA Woman's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
MX2009006912A (es) | 2006-12-28 | 2009-08-12 | Repros Therapeutics Inc | Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas. |
CN101720321B (zh) * | 2007-03-07 | 2012-12-05 | 詹森药业有限公司 | 作为选择性受体调节剂的甾族衍生物 |
UY31010A1 (es) * | 2007-04-05 | 2008-11-28 | Bayer Schering Pharma Ag | Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion |
AU2008341138A1 (en) * | 2007-12-20 | 2009-07-02 | Teva Women's Health, Inc. | Dosage regimens and pharmaceutical compositions and packages for emergency contraception |
US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
US9180131B2 (en) | 2008-12-12 | 2015-11-10 | Laboratoire Hra Pharma | Method for contraception |
EP2419108B1 (en) | 2009-04-14 | 2016-08-17 | Laboratoire HRA Pharma | Method for on-demand contraception |
-
2010
- 2010-04-13 EP EP10717084.7A patent/EP2419108B1/en not_active Revoked
- 2010-04-13 AU AU2010237120A patent/AU2010237120B8/en active Active
- 2010-04-13 ME MEP-2016-239A patent/ME02548B/me unknown
- 2010-04-13 RU RU2011146058/14A patent/RU2542779C2/ru not_active IP Right Cessation
- 2010-04-13 LT LTEP10717084.7T patent/LT2419108T/lt unknown
- 2010-04-13 NZ NZ615430A patent/NZ615430A/en unknown
- 2010-04-13 PT PT107170847T patent/PT2419108T/pt unknown
- 2010-04-13 HU HUE10717084A patent/HUE029434T2/en unknown
- 2010-04-13 WO PCT/EP2010/054812 patent/WO2010119029A1/en active Application Filing
- 2010-04-13 ES ES10717084.7T patent/ES2602134T3/es active Active
- 2010-04-13 US US13/263,717 patent/US9616073B2/en active Active
- 2010-04-13 PL PL10717084T patent/PL2419108T3/pl unknown
- 2010-04-13 NZ NZ595790A patent/NZ595790A/xx unknown
- 2010-04-13 CN CN2010800163136A patent/CN102395373A/zh active Pending
- 2010-04-13 JP JP2012505146A patent/JP5951480B2/ja active Active
- 2010-04-13 DK DK10717084.7T patent/DK2419108T3/en active
- 2010-04-13 RS RS20160950A patent/RS55331B1/sr unknown
- 2010-04-13 EP EP16181168.2A patent/EP3106167A1/en not_active Withdrawn
- 2010-04-13 CA CA2757496A patent/CA2757496A1/en not_active Abandoned
- 2010-04-13 SI SI201031306T patent/SI2419108T1/sl unknown
- 2010-04-13 BR BRPI1014035A patent/BRPI1014035A2/pt not_active Application Discontinuation
-
2011
- 2011-10-04 IL IL215524A patent/IL215524A0/en unknown
- 2011-10-14 ZA ZA2011/07543A patent/ZA201107543B/en unknown
-
2015
- 2015-03-02 US US14/635,107 patent/US9283233B2/en active Active
-
2016
- 2016-02-05 US US15/016,845 patent/US10159681B2/en active Active
- 2016-06-08 JP JP2016114491A patent/JP2016188232A/ja active Pending
- 2016-11-01 CY CY20161101108T patent/CY1118236T1/el unknown
- 2016-11-02 HR HRP20161437TT patent/HRP20161437T1/hr unknown
- 2016-11-08 SM SM201600399T patent/SMT201600399B/it unknown
-
2017
- 2017-06-14 HK HK17105890.1A patent/HK1232150A1/zh unknown
-
2018
- 2018-12-21 US US16/230,802 patent/US10772897B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5951480B2 (ja) | オンデマンド避妊方法 | |
US20150359802A1 (en) | Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis | |
ES2561491T3 (es) | Anticonceptivos orales para prevenir el embarazo | |
CN101626760A (zh) | 利用递增剂量长周期给药方案进行激素治疗的方法 | |
CA2611779A1 (en) | New regimens for controlled drug delivery devices for contraception | |
CA2872644A1 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
TW200944211A (en) | Method for treating uterine fibroids | |
US9180131B2 (en) | Method for contraception | |
US20140005157A1 (en) | Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational | |
US8962603B2 (en) | Method for post coital contraception in overweight or obese female subjects using ulipristal acetate | |
US20160038510A1 (en) | Progesteron receptor modulators for use in the therapy of uterine fibroids | |
WO2022207631A1 (en) | Methods for providing late luteal contraception | |
Kaunitz et al. | New contraceptive choices. | |
Kubba et al. | The supremacy of comblned oral contraceptives (OCs) is being challenged. For too long combined OCs have been seen as synonymous with contraception, helping to maintain ignorance of alternative methods. Further, the efficacy of these OCs and condoms is often compromised by incorrect or inconsistent use. We particularly welcome developments in male systemic methods, that allow men to share not only in conception but also in contraception, and methods that are completely forgettable once instituted, especially if usable by adolescents. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140422 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140707 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141017 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150421 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150716 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150818 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160216 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160218 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160308 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160510 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5951480 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |